Intelligent nanocatalyst mediated lysosomal ablation pathway to coordinate the amplification of tumor treatment.

The production of reactive oxygen species (ROS) is susceptible to external excitation or insufficient supply of related participants (e.g., hydrogen peroxide (H(2)O(2)) and sensitizer), liming ROS-driven tumor treatment. Additionally, the lysosomal retention effect severely hinders the utilization of ROS-based nanosystems and severely restricted the therapeutic effect of tumors. Therefore, first reported herein an intelligent nanocatalyst, TCPP-Cu@MnO(x) ((Mn(II))(1)(Mn(III))(2.1)(Mn(IV))(2.6)O(9.35)), and proposed a programmed ROS amplification strategy to treat tumors. Initially, the acidity-unlocked nanocatalyst was voluntarily triggered to generate abundant singlet oxygen ((1)O(2)) to mediate acid lysosomal ablation to assist nanocatalyst escape and partially induce lysosomal death, a stage known as lysosome-driven therapy. More unexpectedly, the high-yielding production of (1)O(2) in acid condition (pH 5.0) was showed compared to neutral media (pH 7.4), with a difference of about 204 times between the two. Subsequently, the escaping nanocatalyst further activated H(2)O(2)-mediated (1)O(2) and hydroxyl radical (•OH) generation and glutathione (GSH) consumption for further accentuation tumor therapy efficiency, which is based on the Fenton-like reaction and Russell reaction mechanisms. Therefore, in this system, a program-activatable TCPP-Cu@MnO(x) nanocatalyst, was proposed to efficiently destruct organelle-lysosome via (1)O(2) inducing, and stimulated H(2)O(2) conversion into highly toxic (1)O(2) and •OH in cytoplasm, constituting an attractive method to overcome limitations of current ROS treatment.